<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Abbott Laboratories Inc. | Company News & Executive Profiles - ABT | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/abbott+laboratories+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Abbott Laboratories Inc.]]></description>
	<s:counts start="0" returned="10" found="642" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Abbott Labs' Deal with Teva Pharma Is 'Phat News' for Lipid-Lowering Franchise]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005711/abbott-labs-deal-with-teva-pharmaceuticals-is-phat-news-for-lipid-lowering-franchise/]]></link>
		<description><![CDATA[Abbott Laboratories has settled U.S. patent litigation with Teva Pharmaceutical over Abbott 's blockbuster triglycerides drug TriCor. The licensing agreement is critical to Abbott's longer-term strategy of building a successful lipid management portfolio. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 14 Dec 2009 08:58:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/service+management.html"><![CDATA[Service Management]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT</category>
	</item>
	<item>
		<title><![CDATA[Abbott drug safety in FDA spotlight]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/abbott-drug-safety-fda-spotlight/22758/]]></link>
		<description><![CDATA[Abbott Laboratories gets a one-two safety punch today. First, the FDA issued a reminder warning about birth defects in babies born to pregnant women who take Depakote, the epilepsy drug that's also used in bipolar disorder and against maladies such as migraines. The drug and related versions, such as the...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 04 Dec 2009 08:58:48 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT</category>
	</item>
	<item>
		<title><![CDATA[Merck cholesterol scrips drop as Niaspan rises]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/merck-cholesterol-scrips-drop-niaspan/21831/]]></link>
		<description><![CDATA[Last week, all eyes were on Merck's cholesterol drugs. How did Zetia do in that much-anticipated study pitting it against Abbott Laboratories' Niaspan treatment? Well, the American Heart Association meeting has come and gone, and while the study favored Niaspan, the even-handed media coverage pointed out the trial's shortcomings as well...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 06:51:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/dow+jones+%2526+company+inc..html"><![CDATA[Dow Jones & Company Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cholesterol.html"><![CDATA[Cholesterol]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">ABT,DJ,MRK</category>
	</item>
	<item>
		<title><![CDATA[Abbott Acquires Global Rights to Chronic Pain Treatment]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175030-abbott-acquires-global-rights-to-chronic-pain-treatment%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Abbott Labs ABT recently signed a definitive agreement with PanGenetics BV for a pain candidate, PG110. Under the terms of the agreement, Abbott will acquire global rights to PG110 which is a novel biologic that targets Nerve Growth Factor NGF for the treatment of chronic pain....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 24 Nov 2009 05:13:40 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/absolute+software+corp..html"><![CDATA[Absolute Software Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT,ABT</category>
	</item>
	<item>
		<title><![CDATA[Will Questions over Cholestorol Drug Zetia Create a Major Setback for Merck?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173767-will-questions-over-cholestorol-drug-zetia-create-a-major-setback-for-merck%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   The effectiveness of Merck&#8217;s (MRK - Analyst Report) cholesterol lowering drug Zetia has been put to question following the release of data from a clinical trial comparing Abbott&#8217;s (ABT - Analyst Report) Niaspan (niacin extended-release tablets) plus a statin with Merck&#8217;s Zetia. Although data are not...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 17 Nov 2009 05:41:29 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/absolute+software+corp..html"><![CDATA[Absolute Software Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">ABT,ABT,MRK</category>
	</item>
	<item>
		<title><![CDATA[Niaspan trounces Zetia, spurring debate]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/niaspan-trounces-zetia-spurring-debate/20499/]]></link>
		<description><![CDATA[Well, analysts were right about that much-anticipated cholesterol drug study. Abbott Laboratories' Niaspan pill did indeed beat out Merck's Zetia at unclogging arteries, according to study results presented at the American Heart Association meeting yesterday. Cardiologists expect the data to boost niacin use--and serve as a further drag on sales...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 16 Nov 2009 08:36:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/outcome.html"><![CDATA[outcome]]></category>
		<category domain="http://resources.bnet.com/topic/forbes.html"><![CDATA[Forbes]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">ABT,MRK</category>
	</item>
	<item>
		<title><![CDATA[Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173555-cholesterol-drug-trials-a-victory-for-abbott-means-a-loss-for-merck%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Over the weekend, the results in a small cardiovascular trial came out that compared Merck's MRK Zetia (ezetimibe/simvastatin) against Abbott's ABT Niaspan (time-release niacin). Niacin's an under-appreciated therapy in the field - it has tolerability problems, mainly irritating and uncomfortable hot flushing, but it really does...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 16 Nov 2009 07:41:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/absolute+software+corp..html"><![CDATA[Absolute Software Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">ABT,ABT,MRK</category>
	</item>
	<item>
		<title><![CDATA[Abbott under kickback probe over Depakote sales -]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/abbott-kickback-probe-depakote-sales/19371/]]></link>
		<description><![CDATA[ Abbott Laboratories  this morning confirmed the company's sales and marketing practices of Depakote, the widely used drug to treat  bipolar disorder  and epilepsy, are under federal investigation.  The  U.S. Department of Justice , through the U.S. Attorney for the Western District of  Virginia...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 06 Nov 2009 11:46:30 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[company]]></category>
		<category domain="http://resources.bnet.com/topic/investigation.html"><![CDATA[investigation]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT</category>
	</item>
	<item>
		<title><![CDATA[Abbott Laboratories: Dividend Stock Analysis]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F168880-abbott-laboratories-dividend-stock-analysis%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Dividends4Life submits:  Linked here is a detailed quantitative analysis of Abbott Laboratories ABT. Below are some highlights from the above linked analysis: by Dividends4Life]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 26 Oct 2009 08:49:03 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/dividends4life.html"><![CDATA[Dividends4Life]]></category>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/absolute+software+corp..html"><![CDATA[Absolute Software Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT,ABT</category>
	</item>
	<item>
		<title><![CDATA[Abbott Laboratories, Q3 2009 (Qtr End 09/30/09) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-352683.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions.  Our first question today is from Frederick Wise - Leerink Swann, LLC. Frederick Wise - Leerink Swann, LLC  Excellent quarter.  Just trying to understand a little better, gross margin, if you could start with that, tell me if I understand...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 14 Oct 2009 12:04:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/margin.html"><![CDATA[Margin]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/humira.html"><![CDATA[Humira]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/absolute+software+corp..html"><![CDATA[Absolute Software Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT,ABT</category>
	</item>
</channel>
</rss>
